India Daily Briefing

SEBI issued its observation letter approving the National Stock Exchange IPO, with sources pointing to a price band around ₹1,800 and listing by September 25. NSE's IPO has been one of the most delayed in Indian capital markets history — regulatory concerns around market dominance and governance kept it in limbo for years. This is a direct play on India's domestic retail participation boom: NSE's cash equity volumes have compounded ~18% annually over five years, and an exchange listing creates a feedback loop where the instrument of Indian retail investing is itself a retail investment opportunity. Anchor allocation will be the first institutional conviction read.

Friday's US non-farm payrolls came in hot — and Indian FII desks immediately moved to reduce exposure, selling ₹3,112cr net. DII responded with ₹8,930cr of net buying, a near-3x buffer that prevented any index damage. Mint Markets reported that US bond yields and interest rate jitters were the specific drag on Indian equities, with the FII selling concentrated in large-cap exporters sensitive to USD strength. This FII-DII divergence is the structural story of 2026: SIP flows running at ₹25,000cr+/month have given domestic funds a permanent bid, meaning FII selling increasingly creates reallocation opportunities rather than crashes.

Fosun Pharma divested 99 lakh shares of Gland Pharma worth approximately ₹2,800cr in a block deal on Friday, reducing its promoter stake in the Indian injectable pharma company. Economic Times Markets reported that Fosun has been systematically unwinding non-core global holdings as its domestic balance sheet faces pressure — this is a strategic exit, not a read on Gland's operational fundamentals. Block deals of this size require institutional investors on both sides; in a day where FII was a net seller, domestic insurance and mutual funds absorbed the supply. Watch Gland's price action next week for evidence that the block cleared efficiently above market.